{{ logo.lab_name }} {{ logo.lab_address_1 }} {{ logo.lab_address_2 }} {{ logo.state }} {{logo.lab_pincode}}

Sample Name: {{ sample_id }}

Methodology: Real-time RT-PCR

Reporting Date : {{ date_time }}

Test Protocol: {{ test_protocol }}

Result: {{ sample_result }}

{% if test_protocol.lower() == 'mylab tb mtb-rif-inh' or test_protocol.lower() == 'mtb' %}

Interpretive Data: If result is TB negative: This indicates no TB infection. However, if there is a strong history of suggestive TB a repeat test should be done If result is TB is positive and Rifampicin & Isoniazid is sensitive, that indicates TB can be treated with commonly used drugs. If result is Rifampicin and or Isoniazid resistance and patient's clinical history suggest previous TB treatment indicating drug resistance -TB that is difficult to treat with commonly used drugs. which requires specialized management of multidrug resistant TB (MDR TB). If result is Rifampicin and or Isoniazid resistance positive and you have NOT previously taken TB treatment: This may indicate multidrug resistant TB (MDR TB), which requires specialized management

Clinical Significance: MTB RIF&INH Resistance Detection kit can quickly identify possible multidrug-resistant TB (MDR TB). MDR TB is TB that is resistant to both isoniazid (INH) and Rifampicin (RIF), two of the most effective TB drugs. Rapid diagnosis of RIF resistance potentially allows TB patients to start on effective treatment. The information provided by the MTB RIF&INH Resistance Detection kit aids in selecting treatment regimens and reaching infection control decisions quickly.

Limitations: A negative result does not exclude M. tuberculosis infection. PCR-based assays are highly sensitive assays. There are several reasons for paradoxical results, which include contamination during specimen collection, selection of inappropriate specimens, aliquot phenomenon and interference by inherent inhibitors in the sample. Whole blood is not the specimen of choice in patients suspected of having pulmonary or extra pulmonary tuberculosis. The test should be performed on any uncontaminated specimen from the suspected site for which Mycobacteria are a consideration.

{% else %}

Interpretive Data:The Limit of Detection (LOD or analytical sensitivity):

Analyte Average 95% LOD*
HIV-1 M 17.5 IU/ml
HIV-1 O 18.5 Copies/ml
HIV-2 8.17 IU/ml
HCV 10 IU/ml
HBV 2 IU/ml

The TripleH ID Real Time assay uses one step RT-PCR to detect all three tests using a single tube. Each of these steps incorporates an internal control to validate each reaction. TripleH ID-NAT is a multiplex assay provides simultaneous detection of HIV RNA, HBV DNA and HCV-RNA in clinical specimens, with hydrolysis probe chemistry. The target sequences for the TripleH ID test is in the highly conserved region and hence can detect all genotypes

Clinical Significance: To reduce the risk of transfusion transmitted infections (TTIs) in the recipients, thus providing an additional layer of blood safety

Limitations: PCR-based assays are highly sensitive. There are several reasons for paradoxical results, which include interference by inherent inhibitors and degradation of RNA due to pre-analytical errors. Variation in viral load values can be observed due to non-adherence to specimen collection protocol. Hence collection must be in EDTA vacutainer and the plasma separated and frozen immediately.

{% endif %}
Disclaimer: The test results provided are specific to the specimen and may not fully represent the individual’s overall health. They depend on factors such as sample timing, storage conditions, and the individual’s health at the time of collection. It is crucial for the referring physician to review and correlate these results with other medical information before making a diagnosis or treatment decision. These results are intended as a screening tool and are not definitive. Users of this report assume all risks and responsibility for decisions made based on its information..